AC Immune SA said it saw positive new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti-phosphorylated-Tau vaccine candidate being developed in partnership with Janssen Pharmaceuticals Inc.
The company said ACI-35.030 is the first Alzheimer's disease vaccine candidate designed to generate antibodies targeting pathological pTau in the brain.
AC Immune said results from the trial show that ACI-35.030 treatment led to the strong induction of antibodies specific for pathological forms of Tau such as pTau and its aggregated form, enriched paired helical filaments. Anti-pTau IgG titers increased by two orders of magnitude from baseline already two weeks after the first injection of the mid-dose of ACI-35.030.
Interim safety data further support ACI-35.030's favorable safety and tolerability profile, with no clinically relevant safety concerns observed to date.
As previously reported, the ongoing Phase 1b/2a study has been expanded to include a total of 24 Alzheimer's disease participants in the mid-dose sub-cohort. This expansion was designed to support the advancement of ACI-35.030 into late-stage development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.